ABSTRACT OBJECTIVE: to identify the role of PET-CT in management of chest tumors.
INTRODUCTION
In oncological imaging, the goals are lesion detection and localization, lesion characterization, proper staging, and treatment success. Some of these goals require precise anatomical imaging, whereas others demand molecular techniques. It was, therefore, easily acknowledged that FDG-PET and CT are complementary, and the employment of the two is imperative in the oncological clinical practice (16) .
Lung cancer is the leading cause of cancerrelated deaths, Lung cancer is classified as either non-small cell or small cell lung cancer, with the former accounting for 87% of all lung cancers. The descriptors of the internationally used TNM (tumor-node-metastasis) classification system for staging various cancers include the size of and the degree of locoregional invasion by the primary tumor (T), the extent of regional lymph node involvement (N), and the presence or absence of intrathoracic or distant metastases (M). The goal of such a classification system is to assist clinicians in planning treatment, determining prognosis, evaluating treatment results, and facilitating information exchange between multiple centers(18). The management of oncology patients depends on accurate local staging of tumor spread, the identification of nodal involvement and distant metastases. Staging is important at diagnosis, assessing treatment plans, determining prognosis and evaluating response to treatment (3) .
Indications of PET/CT in chest tumors include the evaluation of the solitary pulmonary nodule, the staging of NSCLC, SCLC, mesothelioma and lymphoma, the monitoring of treatment response, and the assessment for recurrent tumor after radio/chemotherapy. PET-CT is a very powerful imaging tool in thoracic oncology. PET-CT is more accurate than PET or CT (8). Adequate patient preparation rules were strictly followed. Patients were instructed to fast, except for glucose-free hydration for 4-6 h before injection of 18F-FDG.
PATIENTS AND METHODS

Scan protocol
The scan was performed 40-60 min after IV injection of (3.7 MBq/Kg; maximum dose 370 MBq) (0.1 millicurie/kilogram (mCi/kg); maximum dose = 20 mCi/kg) of 18F-FDG. The patients were examined in supine position. A whole body examination was performed starting from skull base to mid thighs.A PET emission scan was performed over several bed positions (5 to 7), each with an axial field of view of approximately 15 cm per bed position with an in-plane spatial resolution of 4 mm covering the same field of view as with CT. IV contrast administration (120 mL of a low-osmolarity iodinated contrast agent (Ultravist 300®,Schering, Berlin, Germany) and negative oral contrast agent (water) for bowel were used.
Data interpretation
Images were reconstructed and viewed on workstation (Syngo Multimodality Workplace, Siemens Medical Solutions), which provided multi-planar reformatted PET, CT and fused PET/CT images with linked cursors as well as MIP PET images in video mode. On interpreting fused PET/CT images, lesions were considered positive when areas of intense FDG uptake (> liver or mediastinal blood pool). Lesions were considered negative when lacking high FDG uptake (≤ liver or mediastinal blood pool) despite suspicious corresponding CT findings if any.
RESULTS
The study included 32 patients of variable chest malignancies (19 male patients, 13 female patients; mean age ± standard deviation SD: 40.19 ± 17.087 years; age range:14-65 years).
The indications for PET/CT examination were variable; 19 patients (59.38 %) were referred for assessment of treatment response, 5 patients (15.63%) for follow up at variable disease stages, 2 patients (6.25%) were referred for assessment before BMT , 3 patients (9.38%) was referred for assessment of locoregional recurrence/residue or distant metastasis, 1 patient (3.13%) was referred for assessment of activity of the residual mass post operatively,1 patient (3.13%) was referred for assessment before determination the treatment line and 1 patient (3.13%) was referred for differentiation between tumoral residue or irradiation pneumonitis ( Table 2) . Table ( 2) The analysis of the aim of the study 28 patients received CTH, 14 received RTH and 12 patients underwent surgery,It is to be noted that in most of patients received mixed lines of treatment that mentioned formerly. CT images were analyzed and we found that in 20 patients out of 32 patients CT images were not conclusive for evaluation of disease process , in 5 patients not conclusive for mass residual follow up, in 2 patients not conclusive for postoperative residual versus postoperative changes, & in 2 patients it was not conclusive for therapeutic response follow up ,in 1 patient it was not conclusive for differentiating between tumoral residue or irradiation pneumonitis, in 1 patient not conclusive for differentiating between residual mass & post therapeutic fibrosis and in 1 patient Not conclusive for evaluation of the disease for preparing for BMT (Table 3) . Table ( 3) Percentage of not conclusive CT findings Then the fused PET/CT images were analyzed and 31out of 32 patients were positive for metabolically active FDG avid tumoral masses and one patient was negative (Table 4) . On follow up studies, 8 patients had disease progression, 7 patient had a negative study (complete remission), 7 patients had disease regression , 4 patient had stationary course , 1 patient had stationary course followed by progressive course , 1 patient had regressive course followed by progressive course , 1 patient marked disease regression then progression then complete remission and 3 patients didn't come for follow up (Table 6 ). 
Aim of the study Frequency Percent
Frequency
PET/CT follow up findings
DISCUSSION
The management of oncology patients depends on accurate local staging of tumor spread, the identification of nodal involvement and distant metastases. Staging is important at diagnosis, assessing treatment plans, determining prognosis and evaluating response to treatment(3). The current study is an antegrade evaluation of different categories of oncology patients suffering from chest tumors.
Current imaging studies provide valuable information, however, not specific enough to aid in clinical management. CT and MRI rely on anatomic and morphologic changes for diagnosing, staging and follow-up however; many lesions remain indeterminate making the distinction between benign and malignant disease a constant challenge. In our study 32 patients out of 32 patients had indeterminate CT findings and have to do PET/CT study. Positron emission tomography (PET) offers a different approach to diagnosis of chest diseases (2).
In our study we delineated the metabolic activity of the disease in 2 patients out of 8 patients in group 1-A(lung tumor patients),1 patient out of 2 patients in group 1-B (pleural tumor patients),in 1 patient out of 3 patients in group 1-C (chest wall tumors), in 5 patients out of 7 patients in group 1-D (mediastinal tumor patients),in 7 patients out of 7 patients in group 1-E (lymphoma patients ), 5 patients out of 5 patients in group II (secondary chest tumors).so we agree with (15).
The assessment of the primary tumor extension is usually based on thoracic CT, occasionally complemented by MRI. Due to the increased image quality of MDCT, scanners can depict with greater confidence an invasion of a tumor in surrounding tissues (19).
In our study, PET/CT allowed better discrimination between the tumor and surrounding consolidative changes in 1 patient out of 8 patients in group A-I (lung tumors). This agrees with the study by (6), who stated that this differentiation helped in proper assessment of the actual size and extensions of the tumour and this is very important if the patient will have operation or radiotherapy.
Accurate mediastinal lymph node staging is particularly important, as in many cases the status of these nodes will determine whether surgical resection of lung cancer is possible (17).
18F-FDG PET is recommended in the official American College of Chest Physicians guidelines for noninvasive staging because of the limited value of chest CT in identifying malignant disease in mediastinal lymph nodes (12) .
Group 1-E, included 7 patients who were referred for assessment after CTH &RTH (i.e. to differentiate between benign fibrosis and residual active lymphoma). PET/CT revealed Positive PET/CT for MA FDG lymphomatous infilteration in all patients (100%) of group 1-E, Follow up studies showed disease regression in 3 patients (42.86%) , marked disease regression followed by progression then complete remission in one patient (14.29 %) and Complete remission in one patient (14.29%), Stationary course was mentioned in one patient (14.29 %).We agree with (4), that PET/CT has been useful in assessment of therapeutic response, because of its improved utility in discriminating benign fibrosis (low-grade or absent 18F-FDG uptake) from residual active lymphoma.
We agree with (1,6, 13,14,21) , that PET-CT is a valuable tool in mediastinal lymph nodes staging , but it should be considered as a good negative modality and when positive mediastinal lymph nodes are detected, invasive mediastinal staging must be performed.
In our study 30 patients out of 32 patients had chemotherapy and /or radiotherapy .PET-CT was very effective in monitoring the response of the primary tumour or the lymph node or distant metastases after chemotherapy and /or radiotherapy(case 5 figure 5)
We agree with (9, 20), that PET-CT is a good tool for monitoring of response to chemotherapy or radiotherapy In our study , 29 patients out of 32 patients had baseline PET-CT studies then had follow up PET-CT studies after radiotherapy and/ or chemotherapy . From these studies 2 patients had disease regression course, 1 patient had disease progression course, 1 patient had disease stationary course, 1 patient had regressive course followed by progressive 821 course, 1 patient had stationary course followed by progressive course 1 patient had negative study (complete remission) in group 1-A(lung tumors), 1 patient had disease progression course and the other patient had disease regression course in group 1-B patients (pleural tumors) , 2 patients negative study (good therapeutic response) in group 1-C(chest wall tumors ) , 1 patient had disease progression course one, two patient had disease regression course , one patient had negative study (good therapeutic response),one patient had negative study (good therapeutic response),one patient had stationary course in group 1-D(mediastinal tumors) , two patient had disease regression course, one patient had marked disease regression then progression then complete remission ,one patient had negative study (complete remission ),one patient had stationary course, one patient had disease progression course in group 1-E (lymphoma patients), 3 patients had disease regression course, one patient had negative study (complete remission ) and one patient had stationary course in group II (secondary chest tumors).
These findings are in agreement with (7, 10, 11), indicating that PET/CT changed the management of patients, by resulting in the elimination of previously planned diagnostic procedures, by resulting in the initiation of a previously unplanned treatment option, or by inducing a change in the planned therapeutic approach. 
CONCLUSION
